Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (2921)	4/27/2020 10:31:55 AM
From: Miljenko Zuanic	Respond to of 3557

<The discrepancy stems is from the timing of FX conversions. Converting the full quarter’s sales from euros to dollars at the end of the quarter yields a different result than converting FX continuously throughout the quarter.> I used average cr reported by Sanofi. Bit difference for Japan sale (different percentage), but can not be that big. It is bit more than that, check 1Q 2019 (e583m v $669.4, cr = 1.15) or 3Q-19 ( e640 v $730.2, cr=1.14), v 1Q 2020, cr = 1.10. ??? Is Bayer reporting Japan third party sale as its own?